Medtronic (NYSE:MDT) said today that it won CE Mark approval in the European Union for its MiniMed 670G hybrid closed-loop insulin management system for Type I diabetes patients age 7 and older.
Fridley, Minn.-based Medtronic said it has clinical programs under way to back expanded indications for the device, which is designed to continuously monitor regulate basal insulin delivery using the company’s SmartGuard algorithm and Guardian Sensor 3. The MiniMed 670G also uses Ascensia Diabetes Care‘s ContourNext Link 2.4 blood glucose monitor. The aim is to keep diabetic patients in the optimal glycemic range of 70-180 mg/dL or 3.9-10 mmol/L.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic wins CE Mark for MiniMed 670G hybrid closed-loop insulin system appeared first on MassDevice.
from MassDevice https://ift.tt/2KiyT2q
Cap comentari:
Publica un comentari a l'entrada